
A line of defeats has been trailing biotech firm Orphazyme the past year, and the company recently announced that it is undergoing an in-court restructuring process.
Anders Vadsholt, Orphazyme’s chief financial officer of six years and acting chief executive as of March, has no comment, he informs MedWatch in a text message.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app